DNLI · XBRL financial data

Denali Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DNLI's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	0*	0	—	—	year only	—	—	—	year only	—	—	—
Revenue from contracts with customers	0*	0	0	0	0*	—	0	0	0*	—	4	18
Cost of goods and services sold	—	—	—	—	—	—	0	0	—	—	0	0
Research and development	108*	107	91	98	100*	116	103	102	98*	104	97	106
Selling, general and administrative	—	—	—	—	—	—	32	35	—	—	36	37
General and administrative	25*	25	25	25	30*	29	32	35	39*	34	—	—
Total operating expenses	133*	132	117	123	130*	146	135	137	137*	137	—	—
Operating income (loss)	(133)*	(118)	(117)	(123)	(130)*	(146)	(135)	(137)	(137)*	(137)	(131)	(127)
Other income (expense)	—	—	—	—	—	—	—	11	—	—	—	197
Income tax expense (benefit)	0*	—	—	—	year only	—	—	—	year only	—	—	—
Net income (loss)	(119)*	(102)	(99)	(107)	(115)*	(133)	(124)	(127)	(129)*	(128)	(128)	70
Earnings per share, basic USD per share	(0.86)*	(0.68)	(0.59)	(0.63)	(0.67)*	(0.78)	(0.72)	(0.74)	(0.73)*	(0.69)	(0.68)	0.37
Earnings per share, diluted USD per share	(0.89)*	(0.68)	(0.59)	(0.63)	(0.67)*	(0.78)	(0.72)	(0.74)	(0.73)*	(0.69)	(0.68)	0.37
Weighted average shares, basic millions of shares	138*	149	169	169	170*	171	171	172	175*	187	187	188
Weighted average shares, diluted millions of shares	134*	149	169	169	170*	171	171	172	175*	187	187	192

Fiscal quarters (DNLI's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	127	61	75	91	175	57	141	91	205	388	202	103
Marketable securities	907	876	821	746	657	761	758	757	663	600	509	413
Marketable securities, non-current	0	491	451	445	359	236	78	25	98	64	230	491
Accounts receivable	—	—	—	—	—	—	—	—	0	—	4	19
Inventory	—	—	—	—	—	—	—	—	0	—	4	26
Prepaid and other current assets	30	37	32	32	32	61	36	34	33	35	35	30
Total current assets	1,064	974	928	869	864	879	935	883	901	1,023	754	592
Property and equipment, net	46	47	48	51	55	58	59	54	52	52	50	48
Right-of-use asset	26	25	25	24	23	22	21	20	19	18	17	16
Total assets	1,154	1,581	1,503	1,454	1,374	1,271	1,166	1,056	1,145	1,266	1,158	1,256
Accounts payable	9	12	14	10	11	8	11	7	3	40	12	14
Accrued liabilities	68	6	6	5	91	7	7	5	95	70	78	82
Total current liabilities	78	83	75	87	102	92	91	90	98	110	90	95
Lease liability, non-current	45	43	41	39	37	34	32	30	27	25	22	19
Total liabilities	123	126	116	136	144	149	139	129	131	340	323	330
Accumulated deficit	(1,116)	(1,218)	(1,317)	(1,424)	(1,539)	(1,672)	(1,796)	(1,923)	(2,052)	(2,180)	(2,308)	(2,237)
Total stockholders' equity	1,031	1,455	1,387	1,318	1,230	1,123	1,027	926	1,014	926	835	926
Total liabilities and equity	1,154	1,581	1,503	1,454	1,374	1,271	1,166	1,056	1,145	1,266	1,158	1,256
Common shares outstanding (cover page) millions of shares	139	143	143	144	145	145	146	147	159	159	160	160

Fiscal quarters (DNLI's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(119)*	(102)	(99)	(107)	(115)*	(133)	(124)	(127)	(129)*	(128)	(128)	70
Stock-based compensation	26*	28	25*	25*	25*	25	25*	25*	24*	23	23*	23*
Depreciation and amortization	2*	2	2*	2*	2*	2	3*	3*	3*	3	4*	4*
Net cash from operating activities	(99)*	(114)	(91)*	(59)*	(84)*	(131)	(75)*	(107)*	(99)*	(131)	(97)*	(117)*
Purchases of property and equipment	2*	2	5*	4*	5*	5	4*	(1)*	2*	2	1*	1*
Net cash from investing activities	73*	(453)	99*	94*	172*	19	158*	58*	21*	94	(104)*	16*
Proceeds from issuing common stock	0*	499	0*	0*	(499)*	0	0*	0*	—	12	0*	0*
Net cash from financing activities	5*	500	7*	(19)*	(4)*	(4)	2*	(1)*	192*	219	15*	3*
Net change in cash	(21)*	(67)	14*	16*	84*	(116)	84*	(50)*	114*	182	(186)*	(99)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Denali Therapeutics	103	18	(117)*	160.3M	4.4 quarters	Q3 FY26 10-QSep 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Schrodinger	247	64	(48)*	not reported	10.9 quarters	Q3 FY26 10-QSep 30, 2026
Mannkind	41	102	(35)*	321.6M	4.2 quarters	Q3 FY26 10-QSep 30, 2026
Novavax	222	68	(94)*	165.0M	9.4 quarters	Q3 FY26 10-QSep 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Innoviva	581	106	42*	71.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 9:33 PM ET. The filing on SEC.gov is the record.